XORTX Net Income From Continuing Ops vs Ebit Analysis

XRTX Stock

USD 1.21 0.03 2.54%

XORTX Therapeutics financial indicator trend analysis is more than just analyzing XORTX Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XORTX Therapeutics is a good investment. Please check the relationship between XORTX Therapeutics Net Income From Continuing Ops and its Ebit accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Net Income From Continuing Ops vs Ebit

Net Income From Continuing Ops vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XORTX Therapeutics Net Income From Continuing Ops account and Ebit. At this time, the significance of the direction appears to have very strong relationship.

The correlation between XORTX Therapeutics' Net Income From Continuing Ops and Ebit is 0.83. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Ebit in the same time period over historical financial statements of XORTX Therapeutics, assuming nothing else is changed. The correlation between historical values of XORTX Therapeutics' Net Income From Continuing Ops and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of XORTX Therapeutics are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Net Income From Continuing Ops i.e., XORTX Therapeutics' Net Income From Continuing Ops and Ebit go up and down completely randomly.

Correlation Coefficient

0.83

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Income From Continuing Ops

Ebit

Most indicators from XORTX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.Selling General Administrative is likely to drop to about 1 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	17.9K	55.5K	139.7K	146.7K
Research Development	669.1K	6.5M	3.2M	1.7M

Reconciled Depreciation Research Development

XORTX Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Short Term Debt	Intangible Assets	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.73	0.82	0.98	-0.27	-0.99	-0.58	0.53	0.99	0.9	0.99	0.76	0.63	-0.25	0.89	1.0	-0.35	-0.43	-0.74	0.91	0.61	-0.62	0.56	0.95	-0.15	0.97
Other Current Liab	0.73		0.94	0.76	-0.41	-0.72	-0.1	0.12	0.72	0.47	0.72	0.17	0.15	-0.35	0.56	0.74	-0.09	-0.15	-0.28	0.58	0.42	-0.38	0.27	0.6	0.16	0.82
Total Current Liabilities	0.82	0.94		0.8	-0.51	-0.81	-0.24	0.44	0.81	0.6	0.81	0.35	0.24	-0.44	0.77	0.83	-0.09	-0.17	-0.34	0.62	0.54	-0.5	0.37	0.74	0.19	0.84
Total Stockholder Equity	0.98	0.76	0.8		-0.23	-0.98	-0.55	0.39	0.98	0.88	0.98	0.71	0.61	-0.19	0.8	0.98	-0.38	-0.45	-0.75	0.92	0.58	-0.58	0.56	0.9	-0.17	0.99
Property Plant And Equipment Net	-0.27	-0.41	-0.51	-0.23		0.2	0.45	-0.33	-0.21	-0.31	-0.21	-0.14	-0.35	-0.19	-0.31	-0.26	0.21	0.28	0.25	-0.31	-0.57	0.56	-0.52	-0.12	0.19	-0.29
Net Debt	-0.99	-0.72	-0.81	-0.98	0.2		0.51	-0.51	-1.0	-0.88	-1.0	-0.73	-0.57	0.28	-0.88	-0.99	0.31	0.38	0.7	-0.89	-0.54	0.54	-0.48	-0.96	0.12	-0.97
Retained Earnings	-0.58	-0.1	-0.24	-0.55	0.45	0.51		-0.49	-0.51	-0.76	-0.51	-0.82	-0.98	-0.44	-0.49	-0.55	0.7	0.77	0.86	-0.78	-0.79	0.84	-0.9	-0.45	0.71	-0.53
Accounts Payable	0.53	0.12	0.44	0.39	-0.33	-0.51	-0.49		0.51	0.55	0.51	0.67	0.38	-0.42	0.83	0.52	-0.15	-0.23	-0.3	0.33	0.57	-0.57	0.44	0.66	0.11	0.34
Cash	0.99	0.72	0.81	0.98	-0.21	-1.0	-0.51	0.51		0.88	1.0	0.73	0.57	-0.29	0.89	0.99	-0.3	-0.37	-0.7	0.88	0.53	-0.54	0.48	0.96	-0.11	0.97
Non Current Assets Total	0.9	0.47	0.6	0.88	-0.31	-0.88	-0.76	0.55	0.88		0.88	0.88	0.79	0.05	0.8	0.88	-0.4	-0.48	-0.87	0.92	0.61	-0.63	0.7	0.84	-0.34	0.85
Cash And Short Term Investments	0.99	0.72	0.81	0.98	-0.21	-1.0	-0.51	0.51	1.0	0.88		0.73	0.57	-0.29	0.89	0.99	-0.3	-0.37	-0.7	0.88	0.53	-0.54	0.48	0.96	-0.11	0.97
Net Receivables	0.76	0.17	0.35	0.71	-0.14	-0.73	-0.82	0.67	0.73	0.88	0.73		0.82	0.0	0.74	0.74	-0.59	-0.65	-0.78	0.78	0.7	-0.72	0.77	0.75	-0.35	0.65
Common Stock Shares Outstanding	0.63	0.15	0.24	0.61	-0.35	-0.57	-0.98	0.38	0.57	0.79	0.57	0.82		0.48	0.47	0.6	-0.7	-0.77	-0.91	0.85	0.73	-0.78	0.85	0.48	-0.78	0.6
Other Stockholder Equity	-0.25	-0.35	-0.44	-0.19	-0.19	0.28	-0.44	-0.42	-0.29	0.05	-0.29	0.0	0.48		-0.48	-0.28	-0.3	-0.3	-0.37	0.17	0.02	-0.08	0.29	-0.44	-0.84	-0.15
Total Liab	0.89	0.56	0.77	0.8	-0.31	-0.88	-0.49	0.83	0.89	0.8	0.89	0.74	0.47	-0.48		0.89	-0.18	-0.27	-0.54	0.68	0.58	-0.58	0.46	0.95	0.08	0.78
Total Current Assets	1.0	0.74	0.83	0.98	-0.26	-0.99	-0.55	0.52	0.99	0.88	0.99	0.74	0.6	-0.28	0.89		-0.35	-0.42	-0.71	0.89	0.61	-0.61	0.54	0.95	-0.13	0.97
Short Long Term Debt Total	-0.35	-0.09	-0.09	-0.38	0.21	0.31	0.7	-0.15	-0.3	-0.4	-0.3	-0.59	-0.7	-0.3	-0.18	-0.35		0.99	0.49	-0.53	-0.73	0.75	-0.77	-0.21	0.53	-0.36
Short Term Debt	-0.43	-0.15	-0.17	-0.45	0.28	0.38	0.77	-0.23	-0.37	-0.48	-0.37	-0.65	-0.77	-0.3	-0.27	-0.42	0.99		0.58	-0.61	-0.8	0.83	-0.84	-0.28	0.56	-0.43
Intangible Assets	-0.74	-0.28	-0.34	-0.75	0.25	0.7	0.86	-0.3	-0.7	-0.87	-0.7	-0.78	-0.91	-0.37	-0.54	-0.71	0.49	0.58		-0.91	-0.56	0.61	-0.71	-0.61	0.65	-0.73
Net Tangible Assets	0.91	0.58	0.62	0.92	-0.31	-0.89	-0.78	0.33	0.88	0.92	0.88	0.78	0.85	0.17	0.68	0.89	-0.53	-0.61	-0.91		0.65	-0.68	0.7	0.77	-0.53	0.92
Non Currrent Assets Other	0.61	0.42	0.54	0.58	-0.57	-0.54	-0.79	0.57	0.53	0.61	0.53	0.7	0.73	0.02	0.58	0.61	-0.73	-0.8	-0.56	0.65		-1.0	0.93	0.47	-0.31	0.58
Other Assets	-0.62	-0.38	-0.5	-0.58	0.56	0.54	0.84	-0.57	-0.54	-0.63	-0.54	-0.72	-0.78	-0.08	-0.58	-0.61	0.75	0.83	0.61	-0.68	-1.0		-0.94	-0.47	0.39	-0.58
Long Term Debt	0.56	0.27	0.37	0.56	-0.52	-0.48	-0.9	0.44	0.48	0.7	0.48	0.77	0.85	0.29	0.46	0.54	-0.77	-0.84	-0.71	0.7	0.93	-0.94		0.39	-0.48	0.54
Non Current Liabilities Total	0.95	0.6	0.74	0.9	-0.12	-0.96	-0.45	0.66	0.96	0.84	0.96	0.75	0.48	-0.44	0.95	0.95	-0.21	-0.28	-0.61	0.77	0.47	-0.47	0.39		0.02	0.87
Deferred Long Term Liab	-0.15	0.16	0.19	-0.17	0.19	0.12	0.71	0.11	-0.11	-0.34	-0.11	-0.35	-0.78	-0.84	0.08	-0.13	0.53	0.56	0.65	-0.53	-0.31	0.39	-0.48	0.02		-0.21
Net Invested Capital	0.97	0.82	0.84	0.99	-0.29	-0.97	-0.53	0.34	0.97	0.85	0.97	0.65	0.6	-0.15	0.78	0.97	-0.36	-0.43	-0.73	0.92	0.58	-0.58	0.54	0.87	-0.21

Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1M	2.3M	17.3M	12.3M	5.5M	5.0M
Other Current Liab	641.5K	728.4K	3.8M	151.4K	87.6K	83.2K
Total Current Liabilities	1.3M	1.0M	4.2M	1.5M	294.9K	280.2K
Total Stockholder Equity	(211.7K)	1.3M	13.1M	7.0M	4.6M	3.1M
Property Plant And Equipment Net	731.0	341.0	0.0	92.5K	23.9K	28.8K
Net Debt	(7.8K)	(171.3K)	(14.8M)	(10.3M)	(3.4M)	(3.6M)
Retained Earnings	(6.8M)	(8.0M)	(7.6M)	(14.1M)	(17.9M)	(17.0M)
Accounts Payable	607.4K	305.8K	324.0K	1.3M	195.8K	186.0K
Cash	58.6K	171.3K	14.8M	10.4M	3.4M	3.6M
Non Current Assets Total	272.7K	234.3K	1.5M	1.5M	1.4M	731.9K
Cash And Short Term Investments	58.6K	171.3K	14.8M	10.4M	3.4M	3.6M
Net Receivables	15.5K	14.4K	40.7K	81.8K	60.7K	35.1K
Common Stock Shares Outstanding	595.5K	740.4K	1.1M	1.5M	2.0M	2.1M
Liabilities And Stockholders Equity	1.1M	2.3M	17.3M	12.3M	5.5M	5.0M
Other Stockholder Equity	683.0K	0.0	(1.4M)	(2.4M)	5.5M	5.8M
Total Liab	1.3M	1.0M	4.2M	5.4M	825.9K	784.6K
Total Current Assets	815.2K	2.1M	15.8M	10.9M	4.1M	4.2M
Short Long Term Debt Total	272.5K	43.3K	50.8K	77.4K	11.5K	10.9K
Intangible Assets	272.4K	234.3K	201.0K	199.4K	175.3K	189.0K
Net Tangible Assets	(484.1K)	1.0M	16.5M	9.2M	10.6M	11.1M
Net Invested Capital	(160.9K)	1.3M	16.7M	7.0M	4.6M	4.6M
Net Working Capital	(484.5K)	1.0M	14.9M	9.4M	3.8M	4.3M
Other Current Assets	741.2K	2.1M	1.0M	379.6K	560.4K	728.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XORTX Net Income From Continuing Ops vs Ebit Analysis

Net Income From Continuing Ops vs Ebit

Net Income From Continuing Ops vs Ebit Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Ebit

XORTX Therapeutics fundamental ratios Correlations

XORTX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

XORTX Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for XORTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash

Other Assets	- 1.0	Non Currrent Assets Other
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Common Stock Shares Outstanding	- 0.98	Retained Earnings